Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1.
Our study aimed to determine the role of cyclooxygenase-2 in the release of prostaglandin-(PG)-I2 following mesenteric traction during abdominal surgery. In a prospective double-blind, randomized, placebo-controlled study, 40 patients electively scheduled for non-laparoscopic abdominal surgery, were pretreated with the cyclooxygenase-2 inhibitor parecoxib (n=20) or placebo (n=20). Heart rate, arterial blood pressure, oxygenation ratio and plasma concentrations of the stable PGI2-metabolite 6-keto-PGF1alpha were compared between groups before injection of parecoxib (-40 min), immediately before mesenteric traction (0 min), and 5, 10, and 30 min thereafter. In addition, plasma concentrations of valdecoxib, the active metabolite of the prodrug parecoxib, were determined. Plasma concentrations of 6-keto-PGF1alpha and heart rate increased in both groups after mesenteric traction. There were no significant differences between groups at individual times in heart rate, arterial blood pressure and plasma concentrations of 6-keto-PGF1alpha. Oxygenation ratio decreased after 10 and 30 min following mesenteric traction in the parecoxib group with a significant difference between treatment groups at 10 and 30 min. Plasma concentrations of valdecoxib revealed therapeutic values. Our data indicate that PGI2 release following mesenteric traction is mediated by cyclooxygenase-1.
Department of Anesthesiology, Regensburg University, 93042 Regensburg, Germany. michael.bucher@klinik.uni-regensburg.de
Michael
M
Bucher
Frieder K
FK
Kees
Barbara
B
Messmann
Dirk
D
Lunz
Stephan
S
Rath
Marek
M
Zelenka
Hans J
HJ
Schlitt
Jonny
J
Hobbhahn
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood / Q000652:urine; D000005:Abdomen / Q000601:surgery*; D001794:Blood Pressure / Q000187:drug effects; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D011464:Epoprostenol / Q000097:blood / Q000378:metabolism* / Q000652:urine; D005260:Female; D005483:Flushing / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007431:Intraoperative Complications / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D007555:Isoxazoles / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000378:metabolism; D011446:Prospective Studies; D013449:Sulfonamides / Q000097:blood; D013514:Surgical Procedures, Operative / Q000009:adverse effects / Q000379:methods; D013610:Tachycardia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
D015121:6-Ketoprostaglandin F1 alpha; D051545:Cyclooxygenase 1; D052246:Cyclooxygenase 2 Inhibitors; D011464:Epoprostenol; D007555:Isoxazoles; D010100:Oxygen; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides; C409945:parecoxib